Cargando…

Treatment of solid tumors with immunotoxins

Immunotoxins are hybrid molecules that generally consist of a toxin coupled with a tumor-specific antibody or antibody fragment that is intended to target and concentrate the toxin within the tumor tissue. The biodistribution, specificity, immunogenicity, and cytotoxic activity of the immunotoxin ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Messmer, Davorka, Kipps, Thomas J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1242142/
https://www.ncbi.nlm.nih.gov/pubmed/16168135
http://dx.doi.org/10.1186/bcr1284
_version_ 1782125603752771584
author Messmer, Davorka
Kipps, Thomas J
author_facet Messmer, Davorka
Kipps, Thomas J
author_sort Messmer, Davorka
collection PubMed
description Immunotoxins are hybrid molecules that generally consist of a toxin coupled with a tumor-specific antibody or antibody fragment that is intended to target and concentrate the toxin within the tumor tissue. The biodistribution, specificity, immunogenicity, and cytotoxic activity of the immunotoxin are but a few of the factors that govern the effectiveness of these compounds in the treatment of patients with cancer. Improvements in design, synthesis, and delivery of these molecules may permit them to become significant components in the arsenal of targeted therapies for cancer.
format Text
id pubmed-1242142
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-12421422005-10-06 Treatment of solid tumors with immunotoxins Messmer, Davorka Kipps, Thomas J Breast Cancer Res Commentary Immunotoxins are hybrid molecules that generally consist of a toxin coupled with a tumor-specific antibody or antibody fragment that is intended to target and concentrate the toxin within the tumor tissue. The biodistribution, specificity, immunogenicity, and cytotoxic activity of the immunotoxin are but a few of the factors that govern the effectiveness of these compounds in the treatment of patients with cancer. Improvements in design, synthesis, and delivery of these molecules may permit them to become significant components in the arsenal of targeted therapies for cancer. BioMed Central 2005 2005-07-12 /pmc/articles/PMC1242142/ /pubmed/16168135 http://dx.doi.org/10.1186/bcr1284 Text en Copyright © 2005 BioMed Central Ltd
spellingShingle Commentary
Messmer, Davorka
Kipps, Thomas J
Treatment of solid tumors with immunotoxins
title Treatment of solid tumors with immunotoxins
title_full Treatment of solid tumors with immunotoxins
title_fullStr Treatment of solid tumors with immunotoxins
title_full_unstemmed Treatment of solid tumors with immunotoxins
title_short Treatment of solid tumors with immunotoxins
title_sort treatment of solid tumors with immunotoxins
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1242142/
https://www.ncbi.nlm.nih.gov/pubmed/16168135
http://dx.doi.org/10.1186/bcr1284
work_keys_str_mv AT messmerdavorka treatmentofsolidtumorswithimmunotoxins
AT kippsthomasj treatmentofsolidtumorswithimmunotoxins